Katja Lehnhoff

Statistics

Publications

Citations

628

H-Index

Active since

2011

Affiliations

Novartis (Switzerland)(Current)

Centre Jean Perrin

University of Duisburg-Essen

Institut Bergonié

University Hospital Olomouc

Katja Lehnhoff is an author at Novartis (Switzerland) specializing in metastatic cancer management, malignant neoplasms, and castration-resistant prostate cancer therapy.

Publications per year

2011–2024

Publications

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17

Neuropathology in Mice Expressing Mouse Alpha-Synuclein

Claus Rieker, Kumlesh K. Dev, Katja Lehnhoff et al. · PLoS ONE · 2011 · 165 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Mutations in <i>CIZ1</i> cause adult onset primary cervical dystonia

Jianfeng Xiao, Ryan J. Uitti, Yu Zhao et al. · Annals of Neurology · 2012 · 137 citations

Life Sciences, Genetics, Molecular Genetics +14

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Oliver Sartor, D.E. Castellano Gauna, Ken Herrmann et al. · Annals of Oncology · 2023 · 68 citations · Full text

Medicine, Oncology, Urology +16

1–4 of 4